CLENIL Pressurised inhalation solution (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Clenil Modulite 50 micrograms per actuation pressurised inhalation solution.
Qualitative and quantitative composition
Beclometasone dipropionate 50 micrograms per metered (ex-valve) dose. For the full list of excipients, see section 6.1.
Pharmaceutical form
Pressurised inhalation solution. Clenil Modulite contains the new propellant HFA-134a and does not contain any chlorofluorocarbons (CFCs). The solution is clear and colourless.
Therapeutic indications
Clenil Modulite is indicated for the prophylactic management of mild, moderate, or severe asthma in adults or children: Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication ...
Posology and method of administration
Posology Clenil Modulite is for inhalation use only. The Volumatic spacer device may be used by patients who have difficulty synchronising aerosol actuation with inspiration of breath. The starting dose ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Patients should be properly instructed on the use of the inhaler to ensure that the drug reaches the target areas within the lungs. Patients should also be informed that Clenil Modulite should be used ...
Interaction with other medicinal products and other forms of interaction
Clenil Modulite contains a small amount of ethanol. There is a theoretical potential for interaction in particularly sensitive patients taking disulfiram or metronidazole. Beclometasone is less dependent ...
Fertility, pregnancy and lactation
There is no experience of the use of this product in pregnancy and lactation in humans. It should not be used in pregnancy or lactation unless the expected benefits to the mother are thought to outweigh ...
Effects on ability to drive and use machines
None reported.
Undesirable effects
Adverse events are listed below by system class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000), ...
Overdose
Acute Inhalation of doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not require emergency action. In these patients treatment should be continued at ...
Pharmacodynamic properties
Pharmacotherapeutic Group: Glucocorticoid ATC Code: R03BA01 Beclometasone dipropionate is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes ...
Pharmacokinetic properties
Absorption when administered via inhalation by a MDI Systemic absorption of unchanged beclometasone dipropionate (BDP) occurs through the lungs. There is negligible oral absorption of the swallowed dose ...
Preclinical safety data
Preclinical safety studies indicate that beclometasone dipropionate shows negligible systemic toxicity when administered by inhalation. The non-CFC propellant HFA-134a has been shown to have no toxic effect ...
List of excipients
HFA-134a Ethanol Glycerol
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
Do not store above 30°C. As with most inhaled medicines in aerosol canisters, the therapeutic effect may decrease when the canister is cold. Protect from frost and direct sunlight. The canister contains ...
Nature and contents of container
Clenil Modulite 50 is supplied in an aluminium canister fitted with a metering valve, actuator and dust cap. Each inhaler delivers 200 actuations.
Special precautions for disposal and other handling
Not applicable.
Marketing authorization holder
Chiesi Limited, 333 Styal Road, Manchester, M22 5LG, United Kingdom
Marketing authorization number(s)
PL 08829/0133
Date of first authorization / renewal of the authorization
29/06/2006 / 11/10/12
Date of revision of the text
12/2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: